NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News

Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIGR shares have decreased by 0.1% and is now trading at $6.80. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Eiger Biopharmaceuticals.

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) posted its earnings results on Friday, March, 13th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.30. View Eiger Biopharmaceuticals' earnings history.

5 brokerages have issued twelve-month price objectives for Eiger Biopharmaceuticals' stock. Their forecasts range from $10.72 to $35.00. On average, they expect Eiger Biopharmaceuticals' share price to reach $24.68 in the next year. This suggests a possible upside of 262.9% from the stock's current price. View analysts' price targets for Eiger Biopharmaceuticals.

Media stories about EIGR stock have been trending very negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View the latest news aboutEiger Biopharmaceuticals.

Eiger Biopharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 961,600 shares, an increase of 14.5% from the February 27th total of 840,100 shares. Based on an average trading volume of 399,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 4.5% of the company's shares are short sold. View Eiger Biopharmaceuticals' Current Options Chain.

Some companies that are related to Eiger Biopharmaceuticals include Aerie Pharmaceuticals (AERI), GENFIT S A/ADR (GNFT), Passage Bio (PASG), BAVARIAN NORDIC/S (BVNRY), Avrobio (AVRO), Atara Biotherapeutics (ATRA), Compugen (CGEN), Proteon Therapeutics (PRTO), Innate Pharma (IPHA), Aptose Biosciences (APTO), MeiraGTx (MGTX), DBV TECHNOLOGIE/S (DBVT), Mesoblast (MESO), Vericel (VCEL) and Scholar Rock (SRRK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Progenics Pharmaceuticals (PGNX), Gilead Sciences (GILD), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE), Exelixis (EXEL) and Catalyst Pharmaceuticals (CPRX).

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EIGR stock can currently be purchased for approximately $6.80.

Eiger Biopharmaceuticals has a market capitalization of $167.00 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe. View additional information about Eiger Biopharmaceuticals.

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at ic[email protected]